Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
STP-601
- Development stage
- Unknown
- Lead developer
- Sirnaomics
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Intravitreal
01
Overview
STP-601 is an investigational **intravitreal multi-siRNA nanoparticle formulation** developed by Sirnaomics for ocular neovascularization disorders. The defined siRNA cocktail was reported to suppress the VEGF signaling axis by silencing messenger RNAs encoding vascular endothelial growth factor and its receptors VEGFR1 and VEGFR2, with the aim of reducing pathological retinal and choroidal angiogenesis. It was pursued for diabetic retinopathy, wet age-related macular degeneration, and herpetic stromal keratitis; Sirnaomics licensed Greater China and Southeast Asia development and commercialization rights to Guangdong Zhongsheng Pharmaceutical in 2011. Public sources describe the asset as preclinical or shelved, and its current development activity is not confirmed.
02
Targets
VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on STP-601.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on STP-601.